A Tool to Change Human Antigen R Protein Expression: May Have Implications in both Cancer & Diabetes >


Copyright © 2014 by Dr. Kerry Masterson  ·  All Rights reserved  ·  E-Mail: km@humanantigenr.com

  HuR: A Cancer and Diabetes Target          HuR mRNA Protective Sequence (HPS)           HPS Experiment Results          Contact
Human Antigen R mRNA Protective Sequence Site
PubMed search for HuR AND Pancreatic Cancer

1: McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11. PubMed PMID: 24618665; PubMed Central PMCID: PMC4049785.

2: Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res. 2014 Feb15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915. PubMed PMID: 24536047.

3: Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. 2013 Aug
1;10(8):1312-23. doi: 10.4161/rna.25274. Epub 2013 Jun 13. PubMed PMID: 23807417;PubMed Central PMCID: PMC3817153.

4: Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK,Sachs JN, Brody JR. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther. 2012 Aug;13(10):946-55. doi:10.4161/cbt.20952. Epub 2012 Aug 1. PubMed PMID: 22785201; PubMed Central PMCID: PMC3414415.

5: Brody JR, Gonye GE. HuR's role in gemcitabine efficacy: an exception or opportunity? Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):435-44. doi: 10.1002/wrna.62. Epub 2010 Nov 30. Review. PubMed PMID: 21957028.

6: Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW,  Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455. PubMed PMID: 21152064; PubMed Central PMCID: PMC2994932.

7: Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6. doi: 10.1097/SLA.0b013e3181f1fd44. PubMed PMID: 20739850.

8: Maréchal R, Van Laethem JL. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41. doi: 10.1586/era.09.119. PubMed PMID: 19828005.

9: Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP. 2009 Jul 6;10(4):357-60. PubMed PMID: 19581734.

10: Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 2009 Jun 1;69(11):4567-72. doi: 10.1158/0008-5472.CAN-09-0371. PubMed PMID: 19487279; PubMed Central PMCID: PMC2744447.